Figure 2
Cumulative incidences of new cancer occurrence following initiation of biologics after adjustment for competing mortality. Calculation and comparison of cumulative incidences in the presence of competing risk data ratios were conducted using a modified Kaplan-Meier method and Gray’s method. New cancer occurrence during the first six months was excluded. DMARDs, disease-modifying anti-rheumatic drugs.